SCHEMBL2600670

SCHEMBL2600670

CN(C)C(=O)C(O)c1cncc(-c2cnc3[nH]cc(-c4ccccc4)c3c2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.42
LRRK2 Q5S007 3/20 0.39
GSK3B P49841 2/20 0.39
JAK2 O60674 1/20 0.38
ABL1 P00519 1/20 0.38
SGK1 O00141 4/20 0.37
AXL P30530 4/20 0.37
MAP4K4 O95819 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
PRKD3 O94806 1/20 0.37
EGFR P00533 1/20 0.37
NTRK1 P04629 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
FLT3 P36888 1/20 0.37
FRK P42685 1/20 0.37
CLK2 P49760 1/20 0.37
MAP4K2 Q12851 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2600653 0.91 MAP4K1 (0.43) MAP4K1GSK3BABL1CLK4CLK2
SCHEMBL2112212 0.91 MAP4K1 (0.41) MAP4K1LRRK2GSK3BABL1SGK1
SCHEMBL2600632 0.89 MAP4K1 (0.40) MAP4K1LRRK2GSK3BJAK2ABL1
SCHEMBL2113615 0.87 ABL1 (0.52) MAP4K1LRRK2JAK2ABL1STK4
SCHEMBL2600563 0.86 LRRK2 (0.38) LRRK2GSK3BABL1SGK1AXL
SCHEMBL2600644 0.86 MAP4K1 (0.39) MAP4K1LRRK2GSK3BABL1AXL
SCHEMBL2600639 0.85 MAP4K1 (0.35) MAP4K1ABL1FYNKDRPIM1
SCHEMBL2112218 0.85 MAP4K1 (0.39) MAP4K1ABL1SGK1PLCG1ROCK2
SCHEMBL2112512 0.84 ABL1 (0.41) MAP4K1ABL1CLK2ROCK2NEK1
SCHEMBL2114679 0.84 ABL1 (0.53) MAP4K1LRRK2GSK3BJAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158647-B2 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-8158647-B2 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed
WO-2008150914-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS PDXK, MAP3K4, PDPK1 MAP4K1 16/4885LRRK2 1040/4885GSK3B 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.